VAP-1 Inhibitors Patent, Acucela Inc.

The EPO published patent application EP3856194A2 for VAP-1 (Vascular Adhesion Protein-1) inhibitors developed by Acucela Inc., covering novel heterocyclic compounds classified under C07D 487/04 with pharmaceutical applications under A61K 31/53. The patent designates 44 European Patent Convention contracting states including all major EU markets.\n\nFor pharmaceutical and biotech companies developing drugs targeting VAP-1 for inflammatory or metabolic diseases, this granted patent establishes intellectual property barriers in the European market. Competitors must design around these claims or seek licensing arrangements with Acucela for any VAP-1 inhibitor compounds falling within the protected chemical space.